Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms.
- Author:
Lan HUANG
1
;
Jian-Fang ZHOU
;
Hong WEI
;
Yue-Long SHU
Author Information
1. World Health Organization Global Influenza Collaboration, Centre for Reference and Research, State Key Laboratory for Molecular Virology and Genetic Engineering, Chinese Center for Disease Control and Prevention, National Institute for Viral Disease Control and Prevention, Beijing 102206, China. huanglan301@126.com
- Publication Type:Journal Article
- MeSH:
Animals;
Antiviral Agents;
pharmacology;
Drug Resistance, Viral;
Enzyme Inhibitors;
pharmacology;
Humans;
Influenza, Human;
drug therapy;
virology;
Neuraminidase;
antagonists & inhibitors;
genetics;
metabolism;
Orthomyxoviridae;
drug effects;
enzymology;
genetics;
physiology;
Viral Proteins;
antagonists & inhibitors;
genetics;
metabolism
- From:
Chinese Journal of Virology
2012;28(5):572-576
- CountryChina
- Language:Chinese
-
Abstract:
Influenza viruses are highly contagious for human population and result in acute respiratory infectious diseases ranging from mild to severe. Neuraminidase (NA) inhibitors (NAIs) (oseltamivir, zanamivir, peramivir and laninamivir), which target the NA glycoproteins of influenza A and B viruses are widely used in the prophylaxis and treatment of influenza virus infection. However, the substitutions of amino acids in NA or HA gene may lead to resistances to NAIs. NAI-resistance-related substitutions are typically specific to certain NA type or subtype. The sensitivity for NAI-resistance detection is affected by different assays used.
